Caribou Biosciences (CRBU) Operating Income (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Operating Income of -$26.3 million for Q1 2026, up 38.76% year-over-year from -$18.9 million in Q1 2025, and up 7.64% quarter-over-quarter from -$28.5 million in Q4 2025.
Caribou Biosciences (CRBU) Operating Income (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Operating Income for 7 consecutive years, with -$26.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 38.76% year-over-year to -$26.3 million; the TTM figure through Mar 2026 stood at -$131.7 million (up 19.46% YoY), while the FY2025 annual figure was -$148.3 million, up 10.97% from the prior year.
- Operating Income advanced to -$26.3 million in Q1 2026 per CRBU's latest filing, from -$28.5 million in the prior quarter.
- Across five years, Operating Income topped out at -$14.6 million in Q3 2023 and bottomed at -$47.6 million in Q2 2025.
- Historically, Operating Income has averaged -$33.2 million across 5 years, with a median of -$31.1 million in 2023.
- Annual changes were most pronounced in 2023 — Operating Income surged 44.86% — and 2024, when it slumped 161.31%.
- Caribou Biosciences' Operating Income stood at -$30.6 million in 2022, then dropped by 22.45% to -$37.4 million in 2023, then declined by 3.83% to -$38.9 million in 2024, then climbed by 26.81% to -$28.5 million in 2025, then rose by 7.64% to -$26.3 million in 2026.
- Business Quant data shows CRBU's Operating Income at -$26.3 million in Q1 2026, -$28.5 million in Q4 2025, and -$29.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Caribou Biosciences | 163.09 Mn | 50.78 Mn | - | -25.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.34 Mn |
| Mar 31, 2026 | -26.28 Mn |
| Dec 31, 2025 | -28.45 Mn |
| Sep 30, 2025 | -29.40 Mn |
| Jun 30, 2025 | -47.58 Mn |
| Mar 31, 2025 | -42.91 Mn |
| Dec 31, 2024 | -38.88 Mn |
| Sep 30, 2024 | -38.24 Mn |
| Jun 30, 2024 | -43.50 Mn |
| Mar 31, 2024 | -46.00 Mn |
| Dec 31, 2023 | -37.44 Mn |
| Sep 30, 2023 | -14.63 Mn |
| Jun 30, 2023 | -32.87 Mn |
| Mar 31, 2023 | -31.12 Mn |
| Dec 31, 2022 | -30.58 Mn |
| Sep 30, 2022 | -26.54 Mn |
| Jun 30, 2022 | -28.43 Mn |
| Mar 31, 2022 | -20.85 Mn |
| Dec 31, 2021 | -20.41 Mn |
| Sep 30, 2021 | -18.62 Mn |